Chimeric Antigen Receptor (CAR) T-cell Therapy Billing Instructions

Effective for dates of service on or after 8/7/2019, Medicare will pay claims from approved providers for administration of autologous T-cells expressing at least one CAR for the treatment for cancer.

We’ve published NCD 110.24: Chimeric Antigen Receptor (CAR) T-cell therapy – Billing Instructions which includes details regarding new approved CAR T-cell product Carvykti as well as Part B (outpatient) billing instructions and pricing information effective for DOS on and after 1/1/2022. View the article in its entirety to learn more.

Posted 2/22/2023